Head of Business Development
United States of America
Martin is an entrepreneurial executive and leader with thirty years of global biopharmaceutical experience. He has achieved senior leadership positions in several multinational pharmaceutical companies, and public and private biotechnology companies. He has successfully closed over $3 billion in corporate development transactions and involvement in $265MM in financings. In addition to his role at Navitor, Martin is currently the Co-Founder and Executive Chairman of Yuma Therapeutics, an early-stage biopharmaceutical company developing small molecule drugs for neurodegenerative conditions, such as Alzheimer’s disease. Martin was the President and CEO of Tokai Pharmaceuticals, an oncology company with a small molecule in Phase 2 for prostate cancer. He was the Founder, President and CEO of USMarketer.com, Inc. a business-to-business marketing services and software development venture. Martin served as chief business officer at Dicerna Pharmaceuticals, an RNA interference platform technology company, where he closed a $1.4 billion partnership with Kyowa Hakko Kirin. He was chief business officer at Synta Pharmaceuticals, a small molecule oncology and inflammatory company, where he completed the company’s IPO and closed a $1 billion collaboration with GlaxoSmithKline for its lead oncology product. Earlier in his career, Martin directed the development and commercialization of several blockbuster brands, including GSK’s Zantac and Zofran; Roche’s Xenical; and Wyeth’s (now Pfizer) Zosyn/Tazocin.